Atlas Trials

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Clinical trial NCT02145403 · COMPLETED

Trial details

NCT number
NCT02145403
Sponsor
University of Michigan Rogel Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hematologic MalignanciesRelapseGraft-Versus-Host Disease
Start date
2014-10-01
Primary completion
2018-11-26
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.